Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Clinical Cancer Research|2024Cited by 10
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancerChangfa Shu, Haian Fu, Taofeek K. Owonikoko et al.|Nature Communications|2025Cited by 7
Data from CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLCRathi N. Pillai, Johann C. Brandes, Seth A. Brodie et al.|Unknown|2023Cited by 0
Supplementary Table S2 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0
Supplementary Table S3 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0